Abstract

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a fragment of human gastric juice protein. It consists of 15 amino acids (GEPPPGKPADDAGLV) with a molecular weight of 1419 Da. The peptide demonstrates remarkable stability in gastric acid and resistance to proteases, enabling oral, topical, and parenteral administration in research settings.

Molecular Background

BPC-157 is a partial sequence of the larger gastric juice protein BPC. Key characteristics include:

• Lacks cysteine residues and disulfide bridges, conferring exceptional stability
• Survives over 24 hours in gastric juice at pH 2.0
• Resistant to trypsin, chymotrypsin, and pepsin digestion
• Amphipathic structure facilitates membrane interaction and cellular uptake

Research Applications

BPC-157 has been investigated in laboratory settings for:

• Gastrointestinal Studies: Mucosal protection and healing mechanisms
• Musculoskeletal Research: Tendon, ligament, and muscle repair models
• Vascular Studies: Angiogenesis and endothelial function
• Neuroprotection: Nerve regeneration and spinal cord research

Proposed Mechanisms

Research has focused on several signaling pathways:

• VEGFR2-Akt-eNOS Axis: Rapid phosphorylation leading to NO production
• FAK-Paxillin Pathway: Essential for cell migration processes
• Growth Hormone Receptor: Upregulation in tendon and muscle tissue
• Nitric Oxide System: Modulation of NO-mediated signaling

Preclinical Research Summary

Published preclinical studies have examined BPC-157 in various models:

• Gastrointestinal injury models (ethanol, NSAID-induced)
• Tendon and ligament transection models
• Muscle crush and regeneration studies
• Corneal healing research
• Periodontal and bone healing models

Technical Specifications

• Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
• Molecular Formula: C62H98N16O22
• Molecular Weight: 1419.53 g/mol
• Purity: ≥99% (HPLC verified)
• Storage: Store lyophilized at -20°C

Current Research Status

As of December 2025, BPC-157 remains primarily a preclinical research compound. The majority of published studies originate from a limited number of research groups. Independent replication and human clinical trials remain areas for future investigation.